Avidity Biosciences, Inc. (RNA)
NASDAQ: RNA · Real-Time Price · USD
31.60
-0.96 (-2.95%)
At close: Mar 28, 2025, 4:00 PM
31.71
+0.11 (0.34%)
After-hours: Mar 28, 2025, 7:56 PM EDT
Avidity Biosciences Employees
Avidity Biosciences had 391 employees as of December 31, 2024. The number of employees increased by 138 or 54.55% compared to the previous year.
Employees
391
Change (1Y)
138
Growth (1Y)
54.55%
Revenue / Employee
$27,870
Profits / Employee
-$824,302
Market Cap
3.80B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 391 | 138 | 54.55% |
Dec 31, 2023 | 253 | 67 | 36.02% |
Dec 31, 2022 | 186 | 61 | 48.80% |
Dec 31, 2021 | 125 | 54 | 76.06% |
Dec 31, 2020 | 71 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
RNA News
- 9 days ago - Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 13 days ago - Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in Phase 1/2 EXPLORE44® Trial - PRNewsWire
- 18 days ago - Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - PRNewsWire
- 4 weeks ago - Avidity Biosciences Honors Rare Disease Day® and Global Efforts to Support People and Families Impacted by Rare Neuromuscular Diseases - PRNewsWire
- 4 weeks ago - Avidity Biosciences Reports Fourth Quarter 2024 Financial Results and Recent Highlights - PRNewsWire
- 4 weeks ago - Avidity Biosciences to Participate in Upcoming Investor Conferences - PRNewsWire
- 2 months ago - Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025 - PRNewsWire
- 3 months ago - Avidity Biosciences Advances With FDA Clearance And Promising Data For Rare Diseases - Seeking Alpha